Topics

CAR-T Therapy for Lymphoma

Cancer Immunotherapy Tumor Microenvironment Cellular Stress Cell Programmed Death

Chimeric antigen receptor T-cell therapy has changed the treatment framework for relapsed or refractory B-cell lymphoma by converting a patient’s T cells into living drugs. The dominant clinical platform targets CD19, a broadly expressed B-lineage surface protein, with a synthetic receptor that joins antibody-like antigen recognition to intracellular T-cell signaling. Second-generation products incorporating a costimulatory domain established durable remissions in patients whose disease had resisted conventional chemoimmunotherapy, leading CAR-T therapy to become standard care across several aggressive and indolent B-cell lymphoma settings. Approval of multiple products also created a real-world population broader than the highly selected participants enrolled in early trials. Current research has therefore moved beyond proving activity toward understanding why responses differ, how to deliver treatment earlier, and how to preserve efficacy without compounding toxicity[1][2].

The CAR binds surface antigen independently of major histocompatibility complex presentation. Antigen engagement clusters the receptor and activates CD3ζ together with CD28- or 4-1BB-derived costimulation, initiating cytotoxic granule release, cytokine production, proliferation, and formation of memory-like progeny. Lymphodepleting chemotherapy creates space and a cytokine environment that supports expansion after infusion. The balance between rapid effector differentiation and a self-renewing memory compartment helps determine whether control persists after the initial response. This mechanism can produce rapid tumor clearance, but it also explains cytokine release syndrome and immune effector cell-associated neurotoxicity. Resistance emerges when lymphoma cells lose or reduce the target, alter death signaling, or create an inhibitory microenvironment, and when infused cells fail to expand, become exhausted, or disappear before residual tumor is eradicated[1][3].

Clinical application now spans large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and other CD19-positive lymphomas, although disease biology, prior therapy, tumor burden, and product characteristics influence outcome. CAR-T therapy can benefit patients with chemotherapy-refractory disease because recognition does not require an intact antigen-processing pathway. Collection, manufacturing time, bridging therapy, and referral access nevertheless affect whether an eligible patient reaches infusion with controlled disease. Infection, prolonged cytopenia, B-cell aplasia, hypogammaglobulinemia, and acute inflammatory toxicities require specialized monitoring. Patients who relapse after CAR-T therapy form a biologically diverse group: some retain CD19 and may respond to alternative immune therapies, whereas others have antigen-negative or lineage-altered disease that demands a different target. These distinctions make biopsy and molecular reassessment important components of post-CAR-T management[2][3].

The central challenge is to separate durable immune surveillance from short-lived activation. Dual- or tandem-target receptors against CD19 plus CD20 or CD22 may reduce antigen escape, while optimized costimulation, manufacturing from less differentiated T cells, and checkpoint-resistant or cytokine-armored designs may improve persistence. Biomarkers of T-cell fitness, lymphoma antigen density, host inflammation, and early CAR expansion could support product selection and timely intervention. Standardized long-term follow-up is also needed to capture immune recovery, late infection, secondary malignancy, patient-reported quality of life, and functional recovery. Future trials must define sequencing with bispecific antibodies, transplantation, and targeted drugs, and test whether earlier use preserves T-cell quality. CAR-T therapy is already transformative for lymphoma, but its next gains will come from matching resistance mechanism to rational engineering and clinically practical rescue strategies[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-P9913A Rituximab (anti-CD20)
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

Species: Human

CD20  
Triple-Negative Breast Cancer   Acute Myeloid Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma   Multiple Myeloma   Multiple Sclerosis   Sickle Cell Disease   Rheumatoid Arthritis  
16
HY-P9913 Rituximab
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   CD20  
Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma   Systemic Lupus Erythematosus   Myasthenia gravis   Multiple Sclerosis   Rheumatoid Arthritis  
16
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-P9952 Belimumab
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research. The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.

Species: Human

TNF Receptor   CD20  
Blood Disease   Systemic Lupus Erythematosus   Myasthenia gravis   Rheumatoid Arthritis  
6
HY-P9963 Blinatumomab
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.

Species: Human

CD19  
Cancer  
3
HY-P99711 Loncastuximab
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349).

Species: Human

CD19   ADC Antibodies  
Cancer  
2
HY-158105 ARV-393
ARV-393 is a BCL6 PROTAC degrader. ARV-393 forms a complex with BCL6 and Cereblon, induces BCL6 ubiquitination, and mediates BCL6 degradation via the ubiquitin-proteasome system. ARV-393 enhances CD20 expression, interferon pathway activity and antigen presentation. ARV-393 induces tumor growth inhibition and regression. ARV-393 can be used in research related to non-Hodgkin's lymphoma, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma and follicular lymphoma.
PROTACs   BCL6   CD20   IFNAR  
Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-P9981 Tafasitamab
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.

Species: Human

Apoptosis  
Cancer   Inflammation or Immune System Disease  
2
HY-P99931 Epcoritamab
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines.

Species: Human

CD3   CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-P9910 Obinutuzumab (FUT8-KO)
Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

Species: Human

CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-N1854 Pinobanksin 3-acetate
Pinobanksin 3-acetate is a flavanone and flavonoid ester with antioxidant activity. Pinobanksin 3-acetate is naturally present in Sonoran propolis, honey, medicinal plants, and forestry coproducts of Pinus caribaea. Pinobanksin 3-acetate exerts anti-colorectal cancer activity by modulating proliferation, apoptosis, cell cycle, and Wnt signaling pathways. Pinobanksin 3-acetate can be used for the research of colon cancer.

Source: Sonoran propolis

Drug Derivative   Apoptosis   Wnt  
Colorectal Cancer  
1
HY-120231 Z-VRPR-FMK
Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression.
MALT1   NF-κB   MMP  
Cancer  
1
HY-P99285 Denintuzumab
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.

Species: Human

ADC Antibodies   CD19  
Leukemia/Lymphoma/Myeloma  
1
HY-153084A CD19 CAR mRNA (Human)
CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia.
mRNA   CD19  
Cancer  
1
HY-P99117 Cadonilimab
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Species: Human

PD-1/PD-L1   CTLA-4  
Inflammation or Immune System Disease   Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99264 Inotuzumab
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Species: Human

ADC Antibodies   CD22   Apoptosis  
Acute Lymphoblastic Leukemia   Non-Hodgkin Lymphoma  
1
HY-D1056B3 Lipopolysaccharides, from Klebsiella pneumoniae
Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct Acute Lung Injury Model.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
1
HY-P99113 Inebilizumab
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.

Species: Human

ADC Antibodies   CD19  
Myasthenia gravis   Multiple Sclerosis  
1
HY-P99033 Mosunetuzumab
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions.

Species: Human

CD20   CD3  
Cancer Immunology   Non-Hodgkin Lymphoma  
1
HY-P99024 Glofitamab
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).

Species: Human

CD20   CD3  
Cancer   Inflammation or Immune System Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P7537 BCL2 Protein, Human (His)
BCL2 Protein regulates the mitochondrial membrane permeability, and inhibits the caspase activity, thereby suppressing the apoptosis in various cell types. BCL2 Protein interacts with BECN1 and AMBRA1, and inhibits the autophagy. BCL2 Protein, Human (His) is the human-derived resombinant BCL2 Protein that is expressed in in E. coli with a His tag at the C-terminus.

Species: Human; Source: E. coli

1
HY-P72101 BCL2 Protein, Mouse (His)
BCL2 protein crucially regulates cell death by controlling mitochondrial membrane permeability. It interacts with caspases in a feedback loop, inhibiting their activity. BCL2 prevents cytochrome c release from mitochondria and binds to apoptosis-activating factor (APAF-1). BCL2 Protein, Mouse (His) is the recombinant mouse-derived BCL2 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Mouse; Source: E. coli

1
HY-P702682 CDK4-CCND1 Protein, Human (Active, sf9, GST, Flag, His)
CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4-CCND1 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK4-CCND1, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK Cyclin-Dependent Kinase 4 (CDK4)

1
HY-P702687 CDK6-CCND1 Heterodimer Protein, Human (Active, sf9, GST, Flag, His)
The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK6-CCND1 Heterodimer, expressed by Sf9 insect cells, with N-Flag, N-His, N-GST labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK Cyclin-Dependent Kinase 6 (CDK6)

1
HY-100866 F1324
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC50 of 1 nM. F1324 exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.
Bcl-2 Family  
Cancer  
/
HY-15579BG MMAF sodium (GMP)
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A.
Microtubule/Tubulin   ADC Payloads  
Cancer  
/
HY-15579G MMAF (GMP)
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A.
Microtubule/Tubulin   ADC Payloads  
Cancer  
/
HY-P11903 dTBP-3
dTBP-3 is a fully D-configured polypeptide competitive inhibitor that targets TIGIT. dTBP-3 can competitively occupy the binding interface between TIGIT and its ligand PVR, block TIGIT-mediated immunosuppressive signals, and reverse the immune exhaustion of NK cells and CD8+ T cells. dTBP-3 possesses anti-proteolytic activity and tumor tissue penetration ability, and can also enhance the tumor penetration capacity and cellular internalization efficiency of nanocarriers. dTBP-3 can be used in studies related to liver cancer, triple-negative breast cancer and non-small cell lung cancer.
Transmembrane Glycoprotein   Drug Intermediate  
Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-100866A F1324 TFA
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC50 of 1 nM. F1324 TFA exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.
Bcl-2 Family  
Cancer  
/
HY-P99851 Detumomab
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).

Species: Human

Others  
Cancer  
/
HY-100866B F1324 acetate
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC50 of 1 nM. F1324 acetate exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.
Bcl-2 Family  
Cancer  
/
HY-P5472 Tumour-associated MUC1 epitope
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)
Transmembrane Glycoprotein  
/
HY-P992417 MT-3724
MT-3724 is a CD20-targeted endotoxin B. MT-3724 binds to CD20, triggers receptor internalization, traffics to the endoplasmic reticulum, and induces permanent ribosomal inactivation to mediate cell killing. MT-3724 can inhibit protein synthesis and promote tumor cell apoptosis. MT-3724 can be used for the research of relapsed or refractory B-cell non-Hodgkin’s lymphomas and diffuse large B-cell lymphoma.

Species: Human

CD20   Apoptosis  
Diffuse Large B-cell Lymphoma  
/
HY-P4544 Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone
Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone is an irreversible MALT1 protein inhibitor. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression.
MALT1   NF-κB   MMP  
Cancer  
/
HY-P99501 Zuberitamab
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.

Species: Human

CD20  
Cancer  
/
HY-P11129 MAGE-A4 (286-294)
MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-­A*02 with an affinity of 560.08 nM and an IC50 of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy.
Others  
Cancer  
/
HY-P991369 EBU-141
EBU-141 is a human monoclonal antibody (mAb) targeting CD75/ST6GAL1. EBU-141 can be used in B-cell lymphoma and multiple myeloma research.

Species: Human

Sialyltransferase  
Cancer  
/
HY-P991345 MEDI-0680
MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research.

Species: Human

PD-1/PD-L1  
Cancer  
/
HY-P11698 Guanidino-G-Clamp-PNA
Guanidino-G-Clamp-PNA is a highly efficient sequence-specific RNA binder and gene silencer. Guanidino-G-Clamp-PNA precisely targets such targets as miR-155 or transthyretin (TTR) mRNA through base pairing: the former regulates tumor-related signaling pathways by reducing microRNA activity, while the latter inhibits the translation of harmful proteins via steric hindrance. Guanidino-G-Clamp-PNA effectively stabilizes DNA/RNA duplexes, induces cancer cell apoptosis, and suppresses tumor growth. In addition, Guanidino-G-Clamp-PNA can be conjugated with targeting ligands to improve tissue-specific delivery and reduce in vivo adverse reactions, and it can also enhance the splicing regulation efficacy of other oligonucleotide platforms (such as PMO) when integrated into them. Guanidino-G-Clamp-PNA is applicable to the research of various diseases including diffuse large B-cell lymphoma and hereditary transthyretin-related amyloidosis.
DNA Alkylator/Crosslinker   Transthyretin (TTR)  
Diffuse Large B-cell Lymphoma  
/
HY-P991839 Anti-CD19 Antibody (FMC63)
Anti-CD19 Antibody (FMC63) is an antibody that binds to CD19, with a human Kd value ranging from 0.42 nM to 149 nM. Anti-CD19 Antibody (FMC63) mediates tumor cell killing, cytokine secretion, stable CAR expression, T cell activation and memory differentiation. Anti-CD19 Antibody (FMC63) fails to eliminate lymphoma cells carrying CD19 point mutations or co-expressing FMC63-CAR19, induces higher levels of activation-induced cell death, and reduces cell persistence. Anti-CD19 Antibody (FMC63) can be used in research related to B-cell non-Hodgkin's lymphoma, B-cell acute lymphoblastic leukemia, relapsed or refractory diffuse large B-cell lymphoma, etc.

Species: Human

CD19  
Acute Lymphoblastic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-141432G NX-1607 (GMP)
NX-1607 (Cbl-b-IN-3) (GMP) is a GMP-grade NX-1607 (HY-141432). GMP-grade small molecules can be used as adjuvant agents in cell therapy. NX-1607 (GMP) enhances antigen recall, reduces T cell exhaustion and increases cytokine production. NX-1607 is an inhibitor of Cbl-b (an E3 enzyme).
E1/E2/E3 Enzyme  
Cancer   Inflammation or Immune System Disease  
/
HY-W703549 Aderbasib-d3
Aderbasib-d3 (INCB007839-d3) is deuterium labeled Aderbasib. Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2+?breast cancer, gliomas, et al.
Isotope-Labeled Compounds   MMP  
/
HY-P990930 Mozistobart
HY-P990930 is an CD22-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

CD22   Antibody-Oligonucleotide Conjugates (AOCs)  
Inflammation or Immune System Disease  
/
HY-153939S Idasanutlin-d3-1
Idasanutlin-d3-1 (RG7388-d3-1) is the deuterated-labeled Idasanutlin (HY-15676). Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.
Isotope-Labeled Compounds   MDM-2/p53   E1/E2/E3 Enzyme   Apoptosis   Pyroptosis   Reactive Oxygen Species (ROS)   Caspase  
Musculoskeletal and Skin Disease   Colorectal Cancer   Melanoma   Neuroblastoma   Osteosarcoma   Non-Small Cell Lung Cancer   Acute Myeloid Leukemia   Non-Hodgkin Lymphoma  
/
HY-P11280A PRAME peptide (425-433) acetate
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma.
Melanocortin Receptor  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Lung Squamous Cell Carcinoma   Squamous Cell Carcinoma  
/
HY-P11779 Ac-RKAA-PABC-MMAE
Ac-RKAA-PABC-MMAE is a Drug-Linker Conjugates for ADC. Ac-RKAA-PABC-MMAE consists of the ADC Cytotoxin MMAE (HY-15162) and a linker. Ac-RKAA-PABC-MMAE can be used for synthesis of ADCs.
Drug-Linker Conjugates for ADC   Microtubule/Tubulin  
Cancer  
/
HY-P1407 Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA
Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA is an irreversible MALT1 protein inhibitor. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression.
MALT1   NF-κB   MMP  
Cancer  
/
HY-P99656 Iladatuzumab
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.

Species: Human

ADC Antibodies  
Cancer  
/
HY-D2188 IMP-2373
IMP-2373 is a low-toxicity activity-based probe targeting covalent pan-deubiquitinase (DUB), which modulates and monitors DUB activity via covalent binding to the catalytic cysteine and active site of DUB. IMP-2373 enables real-time tracking of dynamic intracellular DUB activity in physiologically relevant living cell systems, and quantitative analysis of activity changes induced by pharmacological inhibition or MYC dysregulation. IMP-2373 can be used for research on related diseases such as B-cell lymphoma.
Deubiquitinase  
Leukemia/Lymphoma/Myeloma  
/
HY-P99027 Ieramilimab
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors.

Species: Human

LAG-3  
Triple-Negative Breast Cancer  
/
HY-N3062 Pinobanksin
Pinobanksin has apoptotic induction in a B-cell lymphoma cell line.
Apoptosis  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation  
/
HY-P990120 Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5)
Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) is an anti-rat Kappa Immunoglobulin Light Chain IgG2a monoclonal antibody. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance B cell depletion. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance T cell exhaustion after the injection of CD4 mAb (HY-P990792) and CD8 mAb (HY-P99129). Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can be used for research on immunology.

Species: Rat

Others  
Inflammation or Immune System Disease  
/
HY-P990283 Anti-Mouse CD22 Antibody (Cy34.1)
Anti-Mouse CD22 Antibody (Cy34.1) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD22. Anti-Mouse CD22 Antibody (Cy34.1) can deplete CD22 cells and B cells. Anti-Mouse CD22 Antibody (Cy34.1) can promote microglial phagocytosis. Anti-Mouse CD22 Antibody (Cy34.1) can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease (AD) and neuromyelitis.

Species: Mouse

CD22  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P991490 ISB2001
ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma.

Species: Human

CD38   CD3   TNF Receptor  
Cancer  
/
HY-P9959 Inotuzumab ozogamicin
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody Inotuzumab (HY-P99264) conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22+ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia.

Species: Human

Antibody-Drug Conjugates (ADCs)   CD22  
Acute Lymphoblastic Leukemia   Non-Hodgkin Lymphoma  
/
HY-P99483 Blontuvetmab
Blontuvetmab (AT 004) is a canine-derived CD20 monoclonal antibody, and it is used for research on canine B-cell lymphoma.

Species: Canlupfam

CD20  
Cancer  
/
HY-N0600 Ginsenoside F3
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer.
Interleukin Related   IFNAR   NF-κB  
Digestive System Disease   Cancer Immunology   Digestive System Inflammation  
/
HY-141602 Pinatuzumab vedotin
Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities.
Antibody-Drug Conjugates (ADCs)   CD22   Microtubule/Tubulin  
Cancer  
/
HY-P99613 Favezelimab
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma. For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

LAG-3  
Leukemia/Lymphoma/Myeloma  
/
HY-P991449 LY3415244
LY3415244 is a bispecific antibody that targets and inhibits TIM-3 and PD-L1. LY3415244 blocks the interaction between TIM-3 on immune cells and PD-L1 on the surface of tumor cells, establishes intercellular connections between TIM-3-positive immune cells and PD-L1-positive tumor cells, and blocks dual immunosuppressive signals. LY3415244 alleviates T cell exhaustion and restores T cell proliferation. LY3415244 induces broad-spectrum anti-drug antibodies, which impairs the binding capacity to soluble TIM-3 targets. LY3415244 can be used in research related to various advanced solid tumors.

Species: Human

PD-1/PD-L1   Tim3  
Cancer  
/
HY-P99230 Pinatuzumab
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Integrin   CD22  
Cancer  
/
HY-P990759 Rezetamig
Rezetamig is a human bispecific antibody that recognizes the CD3 antigen on T-lymphocytes and the CD22 antigen on mature and malignant B-lymphocytes.

Species: Human

CD22   CD3  
Inflammation or Immune System Disease  
/
HY-P990781 Suciraslimab
Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

CD22   NOD-like Receptor (NLR)   Interleukin Related   Integrin  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P99034 Moxetumomab
Moxetumomab is a CD22-targeting monoclonal antibody that forms the component of Moxetumomab Pasudotox, a recombinant CD22-targeting immunotoxin. Moxetumomab binds to CD22 on malignant B cells and delivers the PE38 toxin domain to tumor cells. Moxetumomab can be used in research on relapsed or refractory hairy cell leukemia.

Species: Human

CD22  
Leukemia/Lymphoma/Myeloma  
/
HY-P99976 Anti-Mouse CD19 Antibody (1D3)
Anti-Mouse CD19 Antibody (1D3) is an IgG2a antibody inhibitor targeting mouse CD19. Anti-Mouse CD19 Antibody (1D3) reduces CD19 expression levels on the surface of B cells. Anti-Mouse CD19 Antibody (1D3) inhibits the replication of peritoneal B-1a cells.

Species: Mouse

CD19  
Inflammation or Immune System Disease  
/
HY-P99139 Anti-Mouse IL-1b Antibody (B122)
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure.

Species: Mouse

Interleukin Related   Reactive Oxygen Species (ROS)   Ferroptosis  
Blood or Cardio-cerebrovascular Disease   Glioma  
/
HY-P99113A Inebilizumab (FUT8-KO)
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica.

Species: Human

CD19  
Multiple Sclerosis  
/
HY-172736 Toviblideg
Toviblideg (BMS-986458) is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. Toviblideg selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. Toviblideg modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of Toviblideg with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. Toviblideg induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma.
PROTACs   BCL6   CD20  
Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-P99289 Epratuzumab
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases.

Species: Human

CD22  
Leukemia/Lymphoma/Myeloma   Autoimmune Disease  
/
HY-P99868 Duvortuxizumab
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E.

Species: Human

CD19   CD3  
Cancer  
/
HY-P99761 Obexelimab
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus.

Species: Human

CD19   Apoptosis  
Inflammation or Immune System Disease  
/
HY-P9961 Ofatumumab
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL).

Species: Human

CD20  
Cancer  
/
HY-P991028 Surovatamig
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

Species: Human

CD3   CD19   Interleukin Related   TNF Receptor   IFNAR  
Non-Hodgkin Lymphoma  
/
HY-P78917 CD19 Protein, Human (Biotinylated, HEK293, Fc-Avi)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). CD19 Protein, Human (Biotinylated, HEK293, Fc) is the recombinant human-derived CD19 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P70505 CD19 Protein, Human (HEK293, Fc)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). CD19 Protein, Human (HEK293, Fc) is the recombinant human-derived CD19 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P72119 CCND1 Protein, Human (His)
The CCND1 protein is a regulatory component of the cyclin D1-CDK4 complex that coordinates phosphorylation and RB family inhibition to regulate the G(1)/S transition. This promotes the dissociation of E2F from the RB/E2F complex and promotes the transcription of E2F target genes critical for G(1) phase progression. CCND1 Protein, Human (His) is the recombinant human-derived CCND1 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P75439 CD19 Protein, Cynomolgus/Rhesus Macaque (HEK293, His)
CD19 is a signaling component of the B-cell receptor complex that lowers the threshold for antigen-driven activation. CD19 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque, cynomolgus-derived CD19 protein, expressed by HEK293 , with C-His labeled tag.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P72102 BCL6 Protein, Human (GST)
BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human (GST) is the recombinant human-derived BCL6 protein, expressed by E. coli , with N-GST labeled tag.

Species: Human; Source: E. coli

/
HY-P76857 CD19 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His)
CD19 is a signaling component of the B-cell receptor complex that lowers the threshold for antigen-driven activation. CD19 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is the recombinant Rhesus Macaque-derived CD19 protein, expressed by HEK293 , with C-His labeled tag.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

CAR-T Related Proteins CD Antigens Biotinylated Proteins CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P702575 BCL6 Protein, Human
BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human is the recombinant human-derived BCL6 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

/
HY-P702676 CDK2-CCND1 Protein, Human (Active, sf9, GST, Flag, His)
CDK2 is an important serine/threonine protein kinase that plays a critical regulatory role in the cell cycle, especially during meiosis. It phosphorylates various substrates (CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2) and coordinates centrosome duplication and initiation of DNA synthesis at the G1-S transition. CDK2-CCND1 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK2-CCND1, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK Cyclin-Dependent Kinase 2 (CDK2)

/
HY-P704306 FITC-Labeled CD19 Protein, Human (HEK293, hFc)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). FITC-Labeled CD19 Protein, Human (HEK293, hFc) is the recombinant human-derived FITC-Labeled CD19 protein, expressed by HEK293, with C-hFc labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P7833 CD19 Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc)
CD19 is a signaling component of the B-cell receptor complex that lowers the threshold for antigen-driven activation. CD19 Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived CD19 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rhesus Macaque; Cynomolgus; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P701366 CDK6-CCND1 Heterodimer Protein, Human (sf9)
The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND1 Heterodimer protein, expressed by sf9 insect cells , with tag free.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK Cyclin-Dependent Kinase 6 (CDK6)

/
HY-P702223 BCL2 Protein, Rat (Cell-Free, His)
The BCL2 protein is critical for inhibiting apoptosis in different cellular systems and regulates cell death by controlling mitochondrial membrane permeability. BCL2 operates in a feedback loop with caspases, inhibiting caspase activity by preventing cytochrome c release and binding to apoptosis-activating factor (APAF-1). BCL2 Protein, Rat (Cell-Free, His) is the recombinant rat-derived BCL2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Species: Rat; Source: E. coli Cell-free

Enzymes & Regulators

/
HY-P704441 CD19 Protein, Cynomolgus/Rhesus Macaque (CHO, hFc)
CD19 is a signaling component of the B-cell receptor complex that lowers the threshold for antigen-driven activation. CD19 Protein, Cynomolgus/Rhesus Macaque (CHO, hFc) is the recombinant rhesus macaque/cynomolgus-derived CD19 protein, expressed by CHO, with C-hFc labeled tag.

Species: Rhesus Macaque; Cynomolgus; Source: CHO

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P704445 CD19 Protein, Human (CHO, His)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). CD19 Protein, Human (CHO, His) is the recombinant human-derived CD19 protein, expressed by CHO, with C-His labeled tag.

Species: Human; Source: CHO

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P705110 CD19 Protein, Human (Biotinylated, HEK293, His-Avi)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). CD19, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD19 protein, expressed by HEK293, with C-Avi;C-hFc labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CD Antigens Biotinylated Proteins CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P705413 CD19 Protein, Human (HEK293, mFc)
The CD19 protein is a B cell antigen receptor coreceptor that enhances downstream signaling pathways, lowers the activation threshold, and helps B cells respond to antigens. It activates phosphatidylinositol 3-kinase and mobilizes intracellular Ca(2+). CD19, Human (HEK293, mFc) is the recombinant human-derived CD19 protein, expressed by HEK293, with N-6*His labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CD Antigens CD19 B Cell CD Proteins Stem Cell CD Proteins Dendritic Cell CD Proteins

/
HY-P80446 CD19 Antibody (YA543)
CD19 Antibody (YA543) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD19.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P80597 CD19 Antibody (YA807)
CD19 Antibody (YA807) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P80094 Ctip1 Antibody (YA489)
Ctip1 Antibody (YA489) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Ctip1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81536A Bcl-6 Antibody (YA1281)(PBS only)
Bcl-6 Antibody (YA1281) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-6.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85808 Bcl-6 Antibody (YA5500)
Bcl-6 Antibody (YA5500) is a Mouse-derived and non-conjugated IgG3 monoclonal antibody, targeting to Bcl-6.

Host: Mouse; Reactivity: Human, Mouse,

Monoclonal Antibodies Primary Antibodies

/
HY-P81536 Bcl-6 Antibody (YA1281)
Bcl-6 Antibody (YA1281) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-6.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81443 Bcl-10 Antibody (YA1188)
Bcl-10 Antibody (YA1188) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-10.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81443A Bcl-10 Antibody (YA1188)(PBS only)
Bcl-10 Antibody (YA1188) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-10.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P87417A BCL9L Antibody (YA7105)(PBS only)
BCL9L Antibody (YA7105) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BCL9L.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P8F010A FITC-conjugated CD19 Antibody (4G7)
FITC-conjugated CD19 Antibody (4G7) is a Mouse-derived and FITC conjugated monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F010C PE-conjugated CD19 Antibody (4G7)
PE-conjugated CD19 Antibody (4G7) is a Mouse-derived and PE conjugated monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F010F PerCP-conjugated CD19 Antibody (4G7)
PerCP-conjugated CD19 Antibody (4G7) is a Mouse-derived and PerCP conjugated monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F010I APC-conjugated CD19 Antibody (4G7)
APC-conjugated CD19 Antibody (4G7) is a Mouse-derived and APC conjugated monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F058A FITC-conjugated CD19 Antibody (1D3)
FITC-conjugated CD19 Antibody (1D3) is a Rat-derived and FITC conjugated monoclonal antibody, targeting to CD19.

Host: Rat; Reactivity: Mouse

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F058C PE-conjugated CD19 Antibody (1D3)
PE-conjugated CD19 Antibody (1D3) is a Rat-derived and PE conjugated monoclonal antibody, targeting to CD19.

Host: Rat; Reactivity: Mouse

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P80597A CD19 Antibody (YA807)(PBS only)
CD19 Antibody (YA807) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD19.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86647 CD19 Antibody (YA6339)
CD19 Antibody (YA6339) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD19.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86688 Bcl-2 Antibody (YA6380)
Bcl-2 Antibody (YA6380) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86712 Bcl-2 Antibody (YA6404)
Bcl-2 Antibody (YA6404) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86712A Bcl-2 Antibody (YA6404)(PBS only)
Bcl-2 Antibody (YA6404) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/

Keywords

CAR-T therapy | B-cell lymphoma | CD19 | adoptive cell therapy | antigen escape | T-cell exhaustion